ProMACE-MOPP regimen

	WikiDoc Resources for ProMACE-MOPP regimen
Articles
Most recent articles on ProMACE-MOPP regimen Most cited articles on ProMACE-MOPP regimen Review articles on ProMACE-MOPP regimen Articles on ProMACE-MOPP regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on ProMACE-MOPP regimen Images of ProMACE-MOPP regimen Photos of ProMACE-MOPP regimen Podcasts & MP3s on ProMACE-MOPP regimen Videos on ProMACE-MOPP regimen
Evidence Based Medicine
Cochrane Collaboration on ProMACE-MOPP regimen Bandolier on ProMACE-MOPP regimen TRIP on ProMACE-MOPP regimen
Clinical Trials
Ongoing Trials on ProMACE-MOPP regimen at Clinical Trials.gov Trial results on ProMACE-MOPP regimen Clinical Trials on ProMACE-MOPP regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on ProMACE-MOPP regimen NICE Guidance on ProMACE-MOPP regimen NHS PRODIGY Guidance FDA on ProMACE-MOPP regimen CDC on ProMACE-MOPP regimen
Books
Books on ProMACE-MOPP regimen
News
ProMACE-MOPP regimen in the news Be alerted to news on ProMACE-MOPP regimen News trends on ProMACE-MOPP regimen
Commentary
Blogs on ProMACE-MOPP regimen
Definitions
Definitions of ProMACE-MOPP regimen
Patient Resources / Community
Patient resources on ProMACE-MOPP regimen Discussion groups on ProMACE-MOPP regimen Patient Handouts on ProMACE-MOPP regimen Directions to Hospitals Treating ProMACE-MOPP regimen Risk calculators and risk factors for ProMACE-MOPP regimen
Healthcare Provider Resources
Symptoms of ProMACE-MOPP regimen Causes & Risk Factors for ProMACE-MOPP regimen Diagnostic studies for ProMACE-MOPP regimen Treatment of ProMACE-MOPP regimen
Continuing Medical Education (CME)
CME Programs on ProMACE-MOPP regimen
International
ProMACE-MOPP regimen en Espanol ProMACE-MOPP regimen en Francais
Business
ProMACE-MOPP regimen in the Marketplace Patents on ProMACE-MOPP regimen
Experimental / Informatics
List of terms related to ProMACE-MOPP regimen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

ProMACE-MOPP regimen refers to a regimen consisting of prolix (prednisone), methotrexate, adriamycin (doxorubicin), cyclophosphamide, etoposide, mustargen (mechlorethamine), oncovin (vincristine), procarbazine, prednisone used to treat diffuse large B-cell lymphoma^[1] and primary CNS lymphoma.^[2]

Regimen

ProPrednisone

MMethotrexate

AAdriamycin (Doxorubicin)

CCyclophosphamide

EEtoposide

MMustargen (Mechlorethamine)

OOncovin (Vincristine)

PProcarbazine

PPrednisone

Indications

Diffuse large B-cell lymphoma^[1] and primary CNS lymphoma^[2]

References

↑ ^1.0 ^1.1 Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A; et al. (1994). "MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group". J Clin Oncol. 12 (7): 1366–74. PMID 7517442.
↑ ^2.0 ^2.1 Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H; et al. (2005). "Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma". Ann Hematol. 84 (7): 447–55. doi:10.1007/s00277-005-1005-9. PMID 15747120.

[pmid7517442-1] 1.0 ^1.1 Sertoli MR, Santini G, Chisesi T, Congiu AM, Rubagotti A, Contu A; et al. (1994). "MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group". J Clin Oncol. 12 (7): 1366–74. PMID 7517442.

[pmid15747120-2] 2.0 ^2.1 Yamanaka R, Morii K, Shinbo Y, Takeuchi S, Tamura T, Hondoh H; et al. (2005). "Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma". Ann Hematol. 84 (7): 447–55. doi:10.1007/s00277-005-1005-9. PMID 15747120.

[1]

[2]

ProMACE-MOPP regimen

Overview

Regimen

Indications

References

Navigation menu